Published in Br J Cancer on September 13, 2004
The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal (2009) 2.43
Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal (2009) 2.33
Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res (2005) 1.98
Transcriptional regulatory functions of mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein. Antioxid Redox Signal (2009) 1.81
Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxid Redox Signal (2008) 1.58
Single cell trapping and DNA damage analysis using microwell arrays. Proc Natl Acad Sci U S A (2010) 1.53
Activation of APE1/Ref-1 is dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP. Nucleic Acids Res (2005) 1.33
Redox regulation of DNA repair: implications for human health and cancer therapeutic development. Antioxid Redox Signal (2010) 1.31
Going ape as an approach to cancer therapeutics. Antioxid Redox Signal (2009) 1.25
Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration. Mol Cancer Ther (2008) 1.22
Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol Cancer Res (2009) 1.18
Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth. DNA Repair (Amst) (2007) 1.18
DNA repair proteins as molecular targets for cancer therapeutics. Anticancer Agents Med Chem (2008) 1.17
APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Curr Mol Pharmacol (2012) 1.10
Emerging roles of the nucleolus in regulating the DNA damage response: the noncanonical DNA repair enzyme APE1/Ref-1 as a paradigmatical example. Antioxid Redox Signal (2013) 1.08
Functional analysis of novel analogues of E3330 that block the redox signaling activity of the multifunctional AP endonuclease/redox signaling enzyme APE1/Ref-1. Antioxid Redox Signal (2011) 1.03
Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br J Cancer (2010) 1.02
Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth. Mol Cancer Ther (2011) 1.00
Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression. Cancer Invest (2010) 1.00
Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer. Cancer Biol Ther (2011) 0.93
Bcl2 inhibits abasic site repair by down-regulating APE1 endonuclease activity. J Biol Chem (2008) 0.91
Is redox signaling a feasible target for overcoming multidrug resistance in cancer chemotherapy? Front Pharmacol (2014) 0.84
Apurinic/apyrimidinic endonuclease/redox effector factor-1(APE/Ref-1): a unique target for the prevention and treatment of human melanoma. Antioxid Redox Signal (2009) 0.83
Apurinic/apyrimidinic endonuclease-1 is associated with angiogenesis and VEGF production via upregulation of COX-2 expression in esophageal cancer tissues. Am J Physiol Gastrointest Liver Physiol (2013) 0.81
Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer. Front Nutr (2015) 0.78
IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells. PLoS One (2015) 0.78
Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity. DNA Repair (Amst) (2009) 0.75
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest (2001) 5.87
Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med (1999) 4.40
Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J (1999) 3.70
Going APE over ref-1. Mutat Res (2000) 3.63
The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. Proc Natl Acad Sci U S A (1996) 3.34
AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A (1997) 3.21
Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene (2003) 2.96
Activation of apurinic/apyrimidinic endonuclease in human cells by reactive oxygen species and its correlation with their adaptive response to genotoxicity of free radicals. Proc Natl Acad Sci U S A (1998) 2.42
A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res (1994) 1.89
Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem (1999) 1.83
A murine AP-endonuclease gene-targeted deficiency with post-implantation embryonic progression and ionizing radiation sensitivity. Mutat Res (1998) 1.74
Gene expression and the thiol redox state. Free Radic Biol Med (1999) 1.72
Heterozygosity for the mouse Apex gene results in phenotypes associated with oxidative stress. Cancer Res (2001) 1.66
Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res (2001) 1.64
Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin Cancer Res (2001) 1.37
The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin Cancer Res (2002) 1.37
Redox regulation of the DNA repair function of the human AP endonuclease Ape1/ref-1. Antioxid Redox Signal (2001) 1.36
Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem (2002) 1.29
Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res (2002) 1.25
The DNA repair activity of human redox/repair protein APE/Ref-1 is inactivated by phosphorylation. Cancer Res (1997) 1.23
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res (2002) 1.16
Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. Clin Cancer Res (2000) 1.16
Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers. Br J Cancer (1998) 1.15
Activation of APE/Ref-1 redox activity is mediated by reactive oxygen species and PKC phosphorylation. Nucleic Acids Res (2001) 1.14
The apurinic/apyrimidinic endonuclease (APE/ref-1) DNA repair enzyme is elevated in premalignant and malignant cervical cancer. Anticancer Res (1998) 1.13
Chemotherapy for advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2003) 0.96
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res (1999) 0.92
Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res (1996) 0.88
Enhancement of DNA ligase I level by gemcitabine in human cancer cells. Clin Cancer Res (2002) 0.87
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality. Semin Oncol (2002) 0.84
Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences. Clin Cancer Res (1997) 0.83
Induction of DNA ligase I by 1-beta-D-arabinosylcytosine and aphidicolin in MiaPaCa human pancreatic cancer cells. Exp Cell Res (2002) 0.81
Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem (1983) 9.40
Clinical and biological significance of aneuploidy in human tumours. J Clin Pathol (1984) 2.39
Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. J Biol Chem (1992) 1.91
Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry (1985) 1.78
Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry (1993) 1.77
Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res (2000) 1.69
Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res (1984) 1.58
Association of involvement in psychological self-regulation with longer survival in patients with metastatic cancer: an exploratory study. Adv Mind Body Med (2000) 1.48
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer (2009) 1.47
Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res (2001) 1.47
Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan. Lancet (1978) 1.40
Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res (1987) 1.40
Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry (2001) 1.36
Monocytes and macrophages in malignant melanoma. I. Peripheral blood macrophage precursors. Br J Cancer (1977) 1.30
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer (2008) 1.27
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood (1999) 1.24
Immunohistochemical detection of proliferating cells in vivo. J Histochem Cytochem (1987) 1.22
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res (2000) 1.20
Simultaneous detection of mitochondrial respiratory chain activity and reactive oxygen in digitonin-permeabilized cells using flow cytometry. Cytometry (2000) 1.14
High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol (1979) 1.13
Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res (2001) 1.12
Influence of cellular DNA content on disease-free survival of Stage II breast cancer patients. Cancer Res (1984) 1.11
Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. Br J Cancer (1983) 1.11
Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumours of borderline malignancy. Pathology (1984) 1.11
The influence of age on the DNA ploidy levels of breast tumours. Eur J Cancer Clin Oncol (1983) 1.09
Metastatic adeno or undifferentiated carcinoma from an unknown primary site--natural history and guidelines for identification of treatable subsets. Q J Med (1987) 1.08
Contamination of mononuclear cell suspensions obtained from cancer patients by the Böyum method. Br J Cancer (1978) 1.08
The prognostic significance of proliferative activity in poor histology non-Hodgkin's lymphoma: a flow cytometry study using archival material. Eur J Cancer Clin Oncol (1987) 0.99
Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol (1988) 0.97
Measurement of intracellular pH. Methods Cell Biol (1990) 0.96
Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer. Br J Cancer (1985) 0.95
Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood (2001) 0.94
Monocytes and macrophages in malignant melanoma. III. Reduction of nitroblue tetrazolium by peripheral blood monocytes. Br J Cancer (1978) 0.94
Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma (2000) 0.90
Relationships between the mitochondrial permeability transition and oxidative stress during ara-C toxicity. Cancer Res (1997) 0.89
Evaluation of baclofen (Lioresal) for spasticity in multiple sclerosis. Postgrad Med J (1975) 0.89
Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts. Oncogene (1999) 0.89
Measurement of cellular DNA content as an adjunct to diagnostic cytology in malignant effusions. Eur J Cancer Clin Oncol (1984) 0.88
Constitutive expression of P-glycoprotein as a determinant of loading with fluorescent calcium probes. Cytometry (1994) 0.88
Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res (1995) 0.87
Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res (1995) 0.87
Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy. Eur J Cancer (1977) 0.87
A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response. Leukemia (2011) 0.86
ICI D1694 and idoxuridine: a synergistic antitumor combination. Cancer Res (1994) 0.85
p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res (1999) 0.84
Differential effects of depleting agents on cytoplasmic and nuclear non-protein sulphydryls: a fluorescence image cytometry study. Br J Cancer (1995) 0.84
Respiratory chain-generated oxidative stress following treatment of leukemic blasts with DNA-damaging agents. Exp Cell Res (2001) 0.84
An oxidative stress-mediated death pathway in irradiated human leukemia cells mapped using multilaser flow cytometry. Radiat Res (1998) 0.84
Microregional heterogeneity of non-protein thiols in cervical carcinomas assessed by combined use of HPLC and fluorescence image analysis. Clin Cancer Res (2000) 0.83
Association between tissue hypoxia and elevated non-protein sulphydryl concentrations in human cervical carcinoma xenografts. Br J Cancer (1999) 0.82
Measurement of intracellular pH. Methods Cell Biol (1994) 0.82
Transferrin receptor cycling by human lymphoid cells: lack of effect from inhibition of microtubule assembly. Biochem Biophys Res Commun (1986) 0.82
Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis. Br J Cancer (1995) 0.82
Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study. Cytometry A (2003) 0.82
Inhibition of gamma-glutamyl transpeptidase activity decreases intracellular cysteine levels in cervical carcinoma. Cancer Chemother Pharmacol (2004) 0.82
Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence. Br J Cancer (1978) 0.81
Monocytes and macrophages in malignant melanoma IV. Effects of C. parvum on monocyte function. Br J Cancer (1979) 0.81
Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. Br J Cancer (1979) 0.80
Metastatic adenocarcinoma of unknown primary site: abnormalities of cellular DNA content and survival. Eur J Cancer Clin Oncol (1985) 0.80
Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumours. Br J Cancer (1993) 0.80
The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. Cell Death Differ (2001) 0.80
Cell cycle effects of iron depletion on T-47D human breast cancer cells. Exp Cell Res (1985) 0.79
Transport, metabolism, and DNA interaction of melphalan in lymphocytes from patients with chronic lymphocytic leukemia. Cancer Res (1988) 0.79
Differential effects of buthionine sulphoximine in hypoxic and non-hypoxic regions of human cervical carcinoma xenografts. Radiother Oncol (2001) 0.78
Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II. Biochem Cell Biol (1992) 0.78
BAD induces apoptosis in cells over-expressing Bcl-2 or Bcl-xL without loss of mitochondrial membrane potential. Leuk Lymphoma (2001) 0.77
DNA flow cytometry of paraffin-embedded tissue. Cytometry (1984) 0.77
Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Leukemia (1995) 0.77
Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry. Cytometry (1996) 0.76
Protection from radiation-induced DNA single-strand breaks by induction of nuclear metallothionein. Int J Radiat Biol (2000) 0.76
The Queensland Melanoma Project. Br Med J (1979) 0.75
DNA flow cytometric study of 5-fluorouracil used to treat end stage non-Hodgkin's lymphoma. Br J Cancer (1987) 0.75
Effect of phorbol ester on growth of tumors induced by Rous sarcoma virus and on pp60src kinase activity in these tumors. Cancer Res (1987) 0.75
Effect of phorbol myristate acetate on cultured tumor cells derived from different stages of avian sarcoma virus (ASV)-induced neoplastic growth. Exp Biol (1987) 0.75
Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma, and other tumors. Cancer Treat Rep (1978) 0.75
Fine-needle aspiration of bone marrow from sternum. Lancet (1982) 0.75
Gemcitabine-induced acute myositis in a patient with duodenal cancer. Clin Oncol (R Coll Radiol) (2011) 0.75
Imaging of whole tumor cut sections using a novel scanning beam confocal fluorescence MACROscope. J Biomed Opt (2001) 0.75
A comparison of combination chemotherapy using vindesine or vincristine with adriamycin in the treatment of advanced breast carcinoma. Cancer Treat Rev (1980) 0.75
Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer. Cancer Chemother Pharmacol (1985) 0.75
Mitolactol chemotherapy for malignant melanoma: a phase II study. Cancer Treat Rep (1984) 0.75
Letter: Bioavailability of drugs after intramuscular injection. Lancet (1975) 0.75
Feasibility of obtaining breast epithelial cells from healthy women for studies of cellular proliferation. Breast Cancer Res Treat (1997) 0.75
Pharmacology and toxicity of Ip streptozocin in ovarian cancer: a case report. Cancer Treat Rep (1982) 0.75
Macrophage precursors in ovarian carcinoma. Gynecol Oncol (1979) 0.75
Biochemical modulation of iododeoxyuridine by N6-[4-(morpholinosulfonyl)benzyl]-N6-methyl-2,6-diaminobenz[cd]indole glucuronate (AG-331) leading to enhanced cytotoxicity. Biochem Pharmacol (1995) 0.75
Effect of administration of sodium cyanate and melphalan on the lifespan of P388 tumor-bearing CD2F1 mice. Cancer Chemother Pharmacol (1984) 0.75
Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1. Cancer Chemother Pharmacol (1990) 0.75
Differential effects of phorbol ester on tumor cells induced by avian sarcoma virus. Anticancer Res (1987) 0.75